Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3269-3276

  Schey, S A ^a   Fields, P ^a   Bartlett, J B ^a   Clarke, I A ^a   Ashan, G ^a   Knight, R D ^a   Streetly, M ^a   Dalgleish, A G ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; CD45RO ANTIGEN; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; PARAPROTEIN; DRUG DERIVATIVE; THALIDOMIDE;

ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MACROPHAGE; MAXIMUM TOLERATED DOSE; MONOCYTE; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECURRENT DISEASE;

ADMINISTRATION, ORAL; AGED; CYTOKINES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE;

EID: 4344693453     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.052     Document Type: Article

References (32)

1. Raje N, Anderson KC: Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 14:635-640, 2002
2. Schey SA: Thalidomide in the management of multiple myeloma. Hematology 7:291-299, 2002
3. Richardson PG, Barlogie B, Berenson, et al: A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 348:2609-2617, 2003
4. D'Amato RJ, Loughman MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
5. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
6. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade, Immunopharmacology 31:213-221, 1996
7. Moreira AL, Sumpaio EP, Zmuidizinas A, et al: Thalidomide exerts its inhibitory action in tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993
8. Hideshima T, Chauhan D, Schlossman R, et al: The role of tumor necrosis factor in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 20:4519-4527, 2001
9. McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167, 1995
10. Haslett PA, Corral LG, Albert M, et al: Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CDS + subsets. J Exp Med 187:1885-1892, 1998
11. Schey SA, Cavenagh J, Jones RW, et al: An UK myeloma forum phase II study of thalidomide: Long-term follow-up and recommendations for treatment. Leuk Res 27:909-914, 2003
12. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Schey SA: Myeloma: New insights. Eur J Cancer 1:3541, 2004
14. Marriott JB, Muller GW, Stirling D, et al: Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 1:675-682, 2001
15. Dredge K, Dalgleish AG, Marriott JB: Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14:331-335, 2003
16. Corral LG, Haslett PAJ, Muller GW, et al: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163:380-386, 1999
17. Dredge K, Marriott JB, Macdonald CD, et al: Novel thalidomide analogues display antiangiogenic activity independently of immunemodulatory effects. Br J Cancer 87:1166-1172, 2002
18. Dredge K, Marriott JB, Todryk SM, et al: Protective anti-tumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumour cell vaccination is mediated by increased Th1-type immunity. J Immunol 168: 4914-4919, 2002
19. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
20. Urbauer E, Kaufmann H. NÖsslinger T, et al: Thromboembolic events during treatment with thalidomide. Blood 99:4247-4248, 2002
21. Zangari M, Barlogie B, Thertulien R, et al: Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 4:32-35, 2003
22. Neben K, Moehler T, Kraemer A, et al: Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115: 605-608, 2001
23. Giuliani N, Colla S, Lazzaretti M, et al: Proangiogenic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102:638-645, 2003
24. Marriott JB, Clarke IA, Dredge K, et al: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130:75-84, 2002
25. Osterborg A, Yi Q, Henriksson L, et al: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91:2459-2466, 1998
26. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
27. Nakajima A, Kodama T, Morimoto S, et al: Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 161:1901-1907, 1998
28. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441-1452, 1998
29. Frassanito MA, Cusmai A, Dammacco F: Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 125:190-197, 2001
30. Yi Q, Osterborg A, Bergenbrant S, et al: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043-3049, 1995
31. Gollob JA, Schniper CP, Orsini E, et al: Characterization of a novel subset of CD8(+) T cells that expand in patients receiving interleukin-12. J Clin Invest 102:561-575, 1998
32. Rasmussen T, Hansson L, Österborg A, et al: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101:4607-1610, 2003